Inhalon Biopharma
Inhalon Biopharma is a clinical-stage biotechnology company focused on developing innovative inhaled antibody treatments for acute respiratory infections. Their mission is to provide effective and convenient treatment options for conditions such as RSV, hMPV, influenza, and SARS-CoV-2, utilizing a unique 'test-to-treat' model that enhances patient care.
Inhalon Biopharma
What We Do
Inhalon is developing inhaled antibody treatments designed for immediate intervention, self-administration, and effectiveness across all age groups. These treatments utilize a handheld nebulizer to deliver antibody mist directly to the lungs, providing a new standard in respiratory care.
Infectious Diseases
Vaccines
Routes of Administration
Biologics
Key People
Funded Projects
Developing a Self-administered, Fast-acting Inhaled Immunotherapy for COVID-19
Inhalon Biopharma and Celltrion's lead candidate, IN-006, has shown safety and prolonged lung retention in Phase 1 trials, offering a self-administered, fast-acting solution for COVID-19 and other viral threats.
News & Updates
Inhalon Biopharma will present its findings at the Military Health System Research Symposium.
An update on the inhaled monoclonal antibody therapy platform will be provided at the BIO International Convention.
Inhalon will share progress on its inhaled monoclonal antibody therapy at the congress.
Positive results from a study showing the advantages of Inhalon's inhaled antibody platform over traditional systemic dosing.
Inhalon announces two new publications that advance its inhaled antibody treatment platform.
Inhalon will present its product development pipeline at the Biotech Showcase.